• BioMarin Pharmaceutical Inc., of Novato, Calif., said it intends to offer $250 million worth of senior subordinated convertible notes due 2017 in an underwritten public offering, and will grant underwriters a 13-day option to purchase up to an additional $37.5 million of notes to cover overallotments. Merrill Lynch & Co., of New York, is acting as sole book-running manager of the public offering.

• NeurogesX Inc., of San Carlos, Calif., filed an amended terms for its initial public offering. The firm now plans the price for 4 million shares to range between $13 and $15 per share, which would raise $60 million at most. The earlier amount sought in the IPO was up to $69 million. (See BioWorld Today, Feb. 9, 2007.)

No Comments